Revisiting EXTREME in the Immuno-Oncology Era: How to Improve Its Outcomes-Reference-Cited by-同舟云学术

Revisiting EXTREME in the Immuno-Oncology Era: How to Improve Its Outcomes

Published:2021-09-28 Issue:11 Volume:26 Page:899-901
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Szturz Petr¹^ORCID,Vermorken Jan B.²³^ORCID

Affiliation:

1. Medical Oncology, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), Lausanne, Switzerland

2. Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium

3. Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium

Abstract

The choice of first-line palliative treatment has always been one of the crucial decisions in the management of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck not suitable for salvage surgery or full-dose radiotherapy. This commentary highlights trial results that show the importance of treatment sequencing decisions that should be of interest for daily practice.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/onco.13966

Reference17 articles.

1. Systemic Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

2. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study;Burtness;Lancet,2019

3. Management of recurrent and metastatic oral cavity cancer: Raising the bar a step higher;Szturz;Oral Oncol,2020

4. Platinum-based chemotherapy plus cetuximab in head and neck cancer;Vermorken;N Engl J Med,2008

5. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): A multicentre, open-label, randomised, phase 2 trial;Guigay;Lancet Oncol,2021

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Depth of response may predict clinical outcome in patients with recurrent/metastatic head and neck cancer treated with pembrolizumab-containing regimens;Frontiers in Oncology;2023-08-16

2. Systemic Treatment Sequencing and Prediction of First-line Therapy Outcomes in Recurrent or Metastatic Head and Neck Cancer;Critical Issues in Head and Neck Oncology;2023

3. Anti-EGFR-Based Therapy in Recurrent or Metastatic HNSCC – What Difference Does it Make?;Cancer Investigation;2022-10-25

4. Outcomes Among Patients With Mucosal Head and Neck Squamous Cell Carcinoma Treated With Checkpoint Inhibitors;JAMA Otolaryngology–Head & Neck Surgery;2022-10-01